Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis

BMC Infectious Diseases

Filippo Marmont¹  Giovanni Di Perri²  Alessandro Busca¹  Chiara Frairia¹  Ernesta Audisio¹  Ilaria Motta²  Francesco Giuseppe De Rosa² 

[1] SC Haematology II, AOU Città della Salute e della Scienza, San Giovanni Battista Molinette Hospital, Turin, Italy;Department of Medical Sciences, Infectious Diseases, Amedeo di Savoia Hospital, University of Turin, Corso Svizzera 164, 10149 Turin, Italy

关键词: Infections;    Chemotherapy;    Febrile neutropenia;    Levofloxacin prophylaxis;    Neutropenia;    Acute myeloid leukemia;   

Others  :  1138273
DOI  :  10.1186/1471-2334-13-563

 received in 2013-02-04, accepted in 2013-11-18,  发布年份 2013

【 摘 要 】

Background

Infections are a common cause of morbidity and mortality in patients with acute myeloid leukemia (AML). The evidence for efficacy of antibiotic prophylaxis in reducing the mortality rates and the incidence of bacterial infections was also reported by a systematic review published by Cochrane in 2012. The objective of our study was to report the incidence and the etiology of bloodstream infections in patients with AML undergoing levofloxacin prophylaxis during neutropenic episodes.

Methods

This was a retrospective study of patients with diagnosis of AML during 2001–2007.

Results

A total of 81 patients were included in the study. Two hundred and ninetyone neutropenic episodes were studied, of which 181 were febrile. Bacteria isolated from blood cultures were mostly Gram-positives during the induction (80%) and Gram-negatives during the consolidation (72.4%) phases of chemotherapy. Resistance to ciprofloxacin was found in 78.9% of isolated E. coli and it was higher during consolidation and higher than the hospital rate. The production of extended spectrum betalactamases (ESBL) in E. coli strains was reported in 12.1%, below the reported hospital rate during the study period.

Conclusions

Regular microbiology surveillance is needed to better understand the impact of levofloxacin prophylaxis in neutropenic patients. Our study shows that Gram-positive bacteria are predominant during the induction phase of chemotherapy and Gram-negatives during the consolidation. The rate of fluoroquinolone resistance in the latter setting, even higher than the hospital rate, may suggest to reconsider levofloxacin prophylaxis.

【 授权许可】

   
2013 De Rosa et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Han LN, Zhou J, Shuringa JJ, Vellenga E: Treatment strategies in acute myeloid leukemia. Chin Med J (Engl) 2011, 124(9):1409-1421.
• [2]Roboz GJ: Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011, 2011:43-50.
• [3]Freifeld AG, Bow EJ, Sepkowitz KA, et al.: IDSA guidelines clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010, 52(4):e56-e93.
• [4]Rolston KV: New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999, 29:515-521.
• [5]Bucaneve G, Micozzi A, Menichetti F, et al.: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987.
• [6]Gafter-Gvili A, Fraser A, Paul M, et al.: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012, 1:25-27.
• [7]Denning DW: Invasive aspergillosis. Clin Infect Dis 1998, 26:781-805.
• [8]Ascioglu S, Rex JH, de Pauw B, et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
• [9]Corey L, Boeckh M: Persistent fever in patients with neutropenia. N Engl J Med 2002, 346:222-224.
• [10]Chen CY, Tsay W, Tang GL, et al.: Epidemiology of bloodstream infections in patients with hematological malignancies with and without neutropenia. Epidemiol Infect 2010, 138:1044-1051.
• [11]Intermesoli T, Oldani E, Rossi G, et al.: Two-step response-oriented induction predicts long-term outcome of adult patients with standard- and high-risk acute myeloid leukaemia (AML): a Northern Italy Leukaemia Group (NILG) study. In Abstracts of the Fifteenth EHA Annual Meeting. Barcelona: Abstract 649. European Hematology Association; 2010.
• [12]De Rosa FG, Pagani N, Fossati L, et al.: The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection 2011, 39(6):555-561.
• [13]Busca A, Cavecchia I, Locatelli F, et al.: Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis 2012, 14(1):40-48.
• [14]Tumbarello M, Trecarichi EM, Bassetti M, et al.: Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011, 55(7):3485-3490.